Stockreport

Neos Therapeutics Initiates and Completes Dosing in a Phase 1 Trial of NT0502 for the Treatment of Chronic Sialorrhea

NEOS THERAPEUTICS  (NEOS) 
Last neos therapeutics earnings: 8/8 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: neostx.com
PDF DALLAS and FORT WORTH, Texas, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS), a commercial-stage pharmaceutical company developing and manufa [Read more]